Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa

J Inherit Metab Dis. 2005;28(5):787-8. doi: 10.1007/s10545-005-0018-9.

Abstract

Fabry disease is an inherited lysosomal storage disease caused by deficiency of alpha-galactosidase A. Enzyme replacement therapy for this multisystem progressive disease has been available only since 2001. We here report the first known successful pregnancy of a female patient receiving such therapy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Enzyme Therapy
  • Fabry Disease / complications
  • Fabry Disease / therapy*
  • Female
  • Humans
  • Infant, Newborn
  • Isoenzymes / therapeutic use
  • Lysosomal Storage Diseases / complications
  • Lysosomal Storage Diseases / therapy
  • Male
  • Pregnancy
  • Pregnancy Complications*
  • Pregnancy Outcome
  • Recombinant Proteins
  • Treatment Outcome
  • alpha-Galactosidase / metabolism
  • alpha-Galactosidase / therapeutic use*

Substances

  • Isoenzymes
  • Recombinant Proteins
  • agalsidase alfa
  • alpha-Galactosidase